Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Certain FDAMA Provisions Underutilized By Device Firms, Hill Aide Says

This article was originally published in The Gray Sheet

Executive Summary

Manufacturers should be more aggressive in pressing for their rights under the FDA Modernization Act, Senate Labor and Human Resources Health Policy Advisor Jay Hawkins told the Regulatory Affairs Professionals Society Oct. 28 in Washington, D.C.

You may also be interested in...



CDRH FY 2000 Performance Goals Focus On Sponsor Meetings, Review Times

FDA's Center for Devices and Radiological Health is pledging to hold 65% of premarket approval application "determination" and investigational device exemption "agreement" meetings within 30 days of a sponsor's request in fiscal 2000, FDA officials report.

CDRH FY 2000 Performance Goals Focus On Sponsor Meetings, Review Times

FDA's Center for Devices and Radiological Health is pledging to hold 65% of premarket approval application "determination" and investigational device exemption "agreement" meetings within 30 days of a sponsor's request in fiscal 2000, FDA officials report.

FDA Committed To Third-Party Review, Henney Tells Senate HELP Committee

FDA Commissioner Jane Henney is "puzzled" about the low utilization rate within the device industry of the agency's "Accredited Persons" third-party premarket review program, she said at an Oct. 21 Senate Health, Education, Labor and Pensions Committee hearing.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel